PharVision Advisers’s Royal Gold RGLD Stock Holding History

PharVision Advisers’s Portfolio RGLD Stock Details RGLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,135	Closed	-$380K	–	769
2025 Q2	$380K	Buy	+2,135	New	+$378K	0.55%	31

Other funds holding RGLD

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FPP

Findlay Park Partners London, United Kingdom $7.17B AUM 17.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's RGLD Position: Q3 2025 in Review

PharVision Advisers sold out of Royal Gold (RGLD) in Q3 2025, closing a stake of 2,135 shares — an estimated $380K sold.

PharVision Advisers first reported a position in RGLD in Q2 2025 and held it in 1 quarter. The position peaked at $380K in Q2 2025. 650 funds tracked by Wall St. Rank hold RGLD as of Q3 2025.

PharVision Advisers reported no remaining Royal Gold position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 2,135 Royal Gold shares in Q3 2025, an estimated $380K.
PharVision Advisers first reported a position in Royal Gold in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Royal Gold position peaked at $380K in Q2 2025.
650 funds tracked by Wall St. Rank held Royal Gold as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.